BioMedNewsBreaks

FridayMar 14, 2025 2:28 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body’s immune response. Calidi’s pipeline includes three key therapies — RTNova, SuperNova and NeuroNova — that incorporate advanced technologies such as stem cells and antitumor viruses to target and destroy cancer cells. Calidi Biotherapeutics’ innovative therapies hold the potential to revolutionize cancer treatment by enhancing efficacy and stimulating…

Continue Reading

FridayMar 14, 2025 10:24 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Q4 and Full-Year 2024 Financial Results, Highlights FDA Clearance and Commercial Progress 

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advanced cardiac care, announced its financial and operational results for the fourth quarter and full-year 2024. The company achieved key milestones, including FDA 510(k) clearance for the HeartBeam System, the launch of an Early Access Program to refine its clinical workflow, and the submission of an FDA application for its 12-lead ECG synthesis software. HeartBeam also raised $11.5 million in gross proceeds from a public offering to support commercialization efforts. Financially, research and development expenses rose to $11.1 million in 2024 from $6.8 million in 2023, while net loss widened to…

Continue Reading

WednesdayMar 12, 2025 9:40 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients 

Clene (NASDAQ: CLNN) Clene Inc. (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significantly extended survival for patients with ALS. The analysis compared patients receiving CNM-Au8 (Regimen C) to a large concurrent control group (Regimen A) and demonstrated a median survival increase of 6.5 months. The strongest survival benefit was observed in a subset meeting the planned Phase 3 RESTORE-ALS trial criteria, where CNM-Au8 extended median survival by 14.8 months. These findings reinforce CNM-Au8’s potential to enhance ALS patient outcomes as Clene prepares for its confirmatory Phase 3 trial…

Continue Reading

TuesdayMar 11, 2025 10:45 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit 

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, will participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit from March 18-20 in Boston. CEO Maria Maccecchini, Ph.D., will present Phase III data on buntanetap and discuss a holistic approach to targeting neurotoxic proteins on March 19. Annovis will also join a panel on advancing Parkinson’s therapies, emphasizing the need for broader treatment strategies beyond single-target approaches.   To view the full press release, visit https://ibn.fm/nyW4N  About Annovis Bio Inc.  Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as…

Continue Reading

MondayMar 10, 2025 9:59 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform 

Calidi Biotherapeutics (NYSE American: CLDI) announced positive preclinical results for its systemic RTNova platform, demonstrating effective delivery of transient gene therapy payloads to targeted tumors. The tumor-specific virotherapy has shown efficacy across more than 60 tumor cell lines, with a unique vaccinia virus strain enveloped in a human cell membrane providing protection in the bloodstream while targeting distant tumors. In preclinical models, a single dose of the tumor-selective triple knockout (“3KO”) RT virus with an undisclosed immunotherapeutic payload significantly altered the tumor microenvironment, leading to complete tumor eradication in some cases. The findings support the platform’s potential to revolutionize cancer…

Continue Reading

FridayMar 07, 2025 1:39 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Collaborates to Support Potential Accelerated Pathway for ALS Treatment Candidate

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data in evaluating its drug candidate, CNM-Au8®, for ALS treatment. Based in Germany, APST operates one of the largest ALS biomarker repositories, which includes data from over 4,300 ALS patients. This collaboration will enable Clene to compare NfL levels in patients treated with CNM-Au8 against historical ALS controls to assess the drug’s potential in slowing disease progression. The goal is to use these findings to support FDA accelerated approval for CNM-Au8 by demonstrating its ability to reduce NfL…

Continue Reading

ThursdayMar 06, 2025 10:10 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Release Full-Year 2024 Financial Results on March 17 

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced it will release its financial results for the full-year ended Dec. 31, 2024, before market open on March 17, 2025. Executive Chairman and CEO Charles M. Fernandez, CFO Cecile Munnik, and President and CEO of Global Operations David Phipps will host a conference call at 8:30 a.m. Eastern to discuss the results and recent developments.  To view the full press release, visit: https://ibn.fm/xsszX About NextPlat Corp  NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and…

Continue Reading

ThursdayMar 06, 2025 10:08 am

BioMedNewsBreaks — Soligenix Inc. (SNGX) to Present HyBryte™ and SGX302 Data at Dermatology Conferences 

Soligenix (SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that its lead investigators will present findings from recent trials on HyBryte™ for cutaneous T-cell lymphoma (CTCL) and SGX302 for mild-to-moderate psoriasis at the U.S. Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6, 2025, and the American Academy of Dermatology (AAD) Annual Meeting from March 7-11, 2025. Dr. Ellen Kim of the University of Pennsylvania will present data on long-term HyBryte™ treatment for CTCL, while Dr. Neal Bhatia will discuss topical therapy advancements, including synthetic hypericin, at AAD.  To view the full press release, visit https://ibn.fm/CKNb1  About Soligenix, Inc. …

Continue Reading

ThursdayMar 06, 2025 9:47 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at Upcoming Investor and Industry Conferences 

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will participate in two upcoming conferences in Dana Point, Calif. The company will present at the 37th Annual Roth Conference from March 16-18, 2025, at The Laguna Cliffs Marriott Resort & Spa, and at the LSI USA ’25 Conference from March 17-21, 2025, at the Waldorf Astoria, Monarch Beach.  To view the full press release, visit https://ibn.fm/IDU60  About HeartBeam Inc.  HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient…

Continue Reading

ThursdayMar 06, 2025 8:55 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference

Clene (NASDAQ: CLNN) a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced its participation in the 37th Annual Roth Conference. Management will host a virtual fireside chat on March 18, 2025, at 9:20 a.m. PST and conduct one-on-one investor meetings. Interested parties are encouraged to contact their Roth representative for scheduling. To view the full press release, visit https://ibn.fm/TbdFh About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative…

Continue Reading